Who makes Skyrizi and where is it made?
Skyrizi is made by AbbVie Inc., a pharmaceutical company located in North Chicago, Illinois. You can contact AbbVie at 1-800-222-6885 or contact them online at Abbvie.com.
When was Skyrizi approved?
In April 2019 the U.S. Food and Drug Administration (FDA) first approved Skyrizi (risankizumab-rzaa) from Abbvie. It is an interleukin-23 (IL-23) inhibitor for the treatment of plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.
In 2021, Skyrizi was also approved to treat active psoriatic arthritis in adults, and in 2022 it was approved for moderate-to-severe Crohn's disease in adults.
- For plaque psoriasis and psoriatic arthritis, Skyrizi is given as two initiation doses at week 0 and 4 by a subcutaneous (under the skin) injection, then it is given every 12 weeks as a maintenance dose.
- In Crohn’s Disease, an induction dosage is given via intravenous infusion at Week 0, Week 4, and Week 8. Maintenance dosage is then given by a subcutaneous injection at Week 12, then every 8 weeks thereafter.
- Your doctor can give you the Skyrizi injections at the office, or you (or your caregiver), can learn to give them at home (pre-filled pen or syringe).
Related Questions
- What does psoriasis look like?
- How do you get psoriasis and is it contagious?
- How does Tremfya work to treat plaque and psoriatic arthritis?
Does Skyrizi have common side effects?
Common side effects in plaque psoriasis and psoriatic arthritis include upper respiratory infections, headache, fatigue, injection site reactions and tinea (fungal) infections.
In Crohn's disease, common side effects include upper respiratory infections, headache, and arthralgia (joint pain) during the induction period, and arthralgia, injection site reactions, abdominal pain, anemia, pyrexia (fever), back pain, arthropathy (joint disease), and urinary tract infection.
Learn More: Skyrizi Uses and Safety Information
This is not all the information you need to know about Skyrizi (risankizumab-rzaa) for safe and effective use and does not take the place of talking to your doctor about your treatment. Review the full Skyrizi information here, and discuss this information and any questions you have with your doctor or other health care provider.
References
- Skyrizi (risankizumab-rzaa) prescribing information. AbbVie Inc. 6/2022. Accessed June 20, 2022 at https://www.rxabbvie.com/pdf/skyrizi_pi.pdf
Read next
Related medical questions
- What are the new drugs for plaque psoriasis?
- Why should I take folic acid with methotrexate?
- Is triamcinolone acetonide an antifungal cream?
- How do you use clobetasol propionate on your scalp?
- Clobetasol vs. triamcinolone - how do they compare?
- What is a substitute for fluocinonide cream?
- How long does methotrexate stay in your system?
- Halobetasol vs. clobetasol - How do they compare?
- Does taking vitamin D help with psoriasis?
- What causes Plaque Psoriasis?
- Sotyktu vs Otezla: How do they compare?
- Can clobetasol be used for toenail fungus?
- How does Taltz compare to Cosentyx for psoriatic arthritis?
- How long does it take for Skyrizi to work?
- Is fluocinonide an antifungal cream?
- How long should you use fluocinonide for?
- How do you inject Humira?
- Does Feverfew interact with any drugs?
- How long does clobetasol stay in your system?
- Cosentyx vs Humira: How do they compare?
- Who is the actress in the Stelara commercial?
- What's the dosing schedule for Skyrizi?
- What happens if Cosentyx is not refrigerated?
- How long does it take for Sotyktu to work?
- Can Enstilar be used on the scalp?
- What is the mechanism of action of infliximab?
- What is fluocinonide cream good for?
- Does Cosentyx cause weight gain or loss?
- Does Skyrizi cause cancer?
- How long does it take for Tremfya to work?
Drug information
Related support groups
- Psoriasis (97 questions, 305 members)
- Skyrizi (16 questions, 6 members)
- Risankizumab (8 questions, 3 members)
- Crohn's Disease (49 questions, 284 members)
- Plaque Psoriasis (81 questions, 69 members)
- Psoriatic Arthritis (78 questions, 276 members)